Sunshine Biopharma, Inc.
SBFM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $7 | $10 | $8 |
| - Cash | $10 | $16 | $22 | $2 |
| + Debt | $1 | $1 | $1 | $2 |
| Enterprise Value | -$7 | -$9 | -$11 | $7 |
| Revenue | $35 | $24 | $4 | $0 |
| % Growth | 44.7% | 454.4% | 1,802.6% | – |
| Gross Profit | $11 | $8 | $2 | $0 |
| % Margin | 30.6% | 34.6% | 39% | 48.4% |
| EBITDA | -$5 | -$4 | -$26 | -$12 |
| % Margin | -14.8% | -15.9% | -608.5% | -5,294.9% |
| Net Income | -$5 | -$5 | -$27 | -$12 |
| % Margin | -14.7% | -18.7% | -615.4% | -5,444.2% |
| EPS Diluted | -7.32 | -351.36 | -3,523.64 | -9,520 |
| % Growth | 97.9% | 90% | 63% | – |
| Operating Cash Flow | -$13 | -$9 | -$5 | -$2 |
| Capital Expenditures | -$2 | -$1 | -$0 | $0 |
| Free Cash Flow | -$15 | -$10 | -$6 | -$2 |